Tim Lautenschlaeger MD

Tim Lautenschlaeger MD
Clinical Inst HSCollege of Medicinelautenschlaeger.1@osu.edu
385G Wiseman Hall 400 W 12th Avenue Columbus Ohio 43210
Phone:614-247-6432Fax: (614) 292-5275
  • Translational Therapeutics

Research Description

Dr. lautenschlaeger's research involves metabolomic profiling of brain, lung, and gyn tumor tissue and integration with gene expression data with the goal to identify deregulated signaling pathways, novel therapeutic targets, prognostic and predictive metabolomic markers, and novel candidates for metabolomic imaging. He is also involved with the identification and validation of novel therapeutic targets in glioma through identification of novel EGFR pathway modulators.

Current Publications

  • Geiger KD, von Kummer R, Cerhova J, Chakravarti A, Krex D, Schackert G, Juratli TA, Engellandt K, Lautenschlaeger TIs there pseudoprogression in secondary glioblastomas?Int J Radiat Oncol Biol Phys 87 1094-9 12/1/2013
  • Meng W, Ye Z, Cui R, Perry J, Dedousi-Huebner V, Huebner A, Wang Y, Li B, Volinia S, Nakanishi H, Kim T, Suh SS, Ayers LW, Ross P, Croce CM, Chakravarti A, Jin VX, Lautenschlaeger TMicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma.Clin Cancer Res 19 5423-33 10/1/2013
  • Lautenschlaeger T, George A, Klimowicz AC, Efstathiou JA, Wu CL, Sandler H, Shipley WU, Tester WJ, Hagan MP, Magliocco AM, Chakravarti ABladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival.Oncologist 18 685-6 6/1/2013
  • Cottini F, Lautenschlaeger TPredictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.Cancer J 19 263-71 5/1/2013
  • Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Dicker AP, Bredel M, Mehta MRTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.Int J Radiat Oncol Biol Phys 85 1206-11 4/1/2013
  • Lautenschlaeger T, Perry J, Peereboom D, Li B, Ibrahim A, Huebner A, Meng W, White J, Chakravarti AIn vitro study of combined cilengitide and radiation treatment in breast cancer cell lines.Radiat Oncol 8 246 1/1/2013
  • Meng W, McElroy JP, Volinia S, Palatini J, Warner S, Ayers LW, Palanichamy K, Chakravarti A, Lautenschlaeger TComparison of microRNA deep sequencing of matched formalin-fixed paraffin-embedded and fresh frozen cancer tissues.PLoS One 8 e64393 1/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu